Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $416 to $412.